PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, randomized, multicenter, international phase II study for
premenopausal patients with hormone receptor positive, HER2 negative metastatic or locally
advanced breast cancer. Patients will be randomized to receive either palbociclib +
exemestane + OFS (Arm 1) or exemestane +OFS (Arm 2).
Treatment will be continued until disease progression, unacceptable toxicities, or withdrawal
of consent.